156. Rett syndrome Clinical trials / Disease details

Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04988867 (ClinicalTrials.gov)	September 22, 2021	23/7/2021	An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome	An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome	Rett Syndrome	Drug: Trofinetide	ACADIA Pharmaceuticals Inc.	NULL	Active, not recruiting	2 Years	5 Years	Female	15	Phase 2/Phase 3	United States
2	NCT04776746 (ClinicalTrials.gov)	November 8, 2020	29/11/2020	Open-Label Extension Study of Trofinetide for Rett Syndrome	An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome	Rett Syndrome	Drug: trofinetide	ACADIA Pharmaceuticals Inc.	NULL	Enrolling by invitation	5 Years	22 Years	Female	153	Phase 3	United States
3	NCT04279314 (ClinicalTrials.gov)	January 29, 2020	19/2/2020	Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome	A 40-Week, Open-label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome	Rett Syndrome	Drug: Trofinetide	ACADIA Pharmaceuticals Inc.	NULL	Completed	5 Years	21 Years	Female	154	Phase 3	United States
4	NCT04181723 (ClinicalTrials.gov)	November 6, 2019	26/11/2019	Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome	Rett Syndrome	Drug: Trofinetide;Other: Placebo	ACADIA Pharmaceuticals Inc.	NULL	Completed	5 Years	20 Years	Female	187	Phase 3	United States